Review
Microbiology
Fenghao Peng, Naijing Hu, Yingjun Liu, Cong Xing, Longlong Luo, Xinying Li, Jing Wang, Guojiang Chen, He Xiao, Chenghua Liu, Beifen Shen, Jiannan Feng, Chunxia Qiao
Summary: Smallpox is an infectious disease caused by the variola virus, with a high mortality rate. Although smallpox was declared eradicated in 1980, the potential threat of bioterrorism has led to resumed research on the treatment and prevention of smallpox.
FRONTIERS IN MICROBIOLOGY
(2023)
Article
Multidisciplinary Sciences
Steve Lu, Austin K. Mattox, P. Aitana Azurmendi, Ilias Christodoulou, Katharine M. Wright, Maria Popoli, Zan Chen, Surojit Sur, Yana Li, Challice L. Bonifant, Chetan Bettegowda, Nickolas Papadopoulos, Shibin Zhou, Sandra B. Gabelli, Bert Vogelstein, Kenneth W. Kinzler
Summary: The authors developed a method called SLISY to rapidly isolate specific antibodies against SARS-CoV-2 and its variants by simultaneously assessing millions of clones using NGS with phage display. The therapeutic applications of antibodies are diverse, and the emergence of SARS-CoV-2 demonstrates the importance of quickly identifying biologically active antibodies.
NATURE COMMUNICATIONS
(2023)
Article
Biochemistry & Molecular Biology
Naijing Hu, Chunxia Qiao, Jing Wang, Zhihong Wang, Xinying Li, Liuzhong Zhou, Jiaguo Wu, Dingmu Zhang, Jiannan Feng, Beifen Shen, Jinghai Zhang, Longlong Luo
Summary: A novel human antibody named LXY8 was developed in this study to effectively neutralize the toxicity caused by SEB, block the interaction between SEB and the T cell receptor, and inhibit the release of cytokines. Computer-guided molecular modeling identified key residues of SEB important for specific antibody-antigen recognition.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Article
Microbiology
Poonsook Keelapang, Romchat Kraivong, Rojjanaporn Pulmanausahakul, Rungtawan Sriburi, Eakachai Prompetchara, Jutamart Kaewmaneephong, Nicha Charoensri, Pattarakul Pakchotanon, Thaneeya Duangchinda, Piyanan Suparattanagool, Prasit Luangaram, Promsin Masrinoul, Juthathip Mongkolsapaya, Gavin Screaton, Kiat Ruxrungtham, Prasert Auewarakul, Sutee Yoksan, Prida Malasit, Chunya Puttikhunt, Chutitorn Ketloy, Nopporn Sittisombut
Summary: This study describes a blockade-of-binding assay to determine antibodies recognizing particular epitopes in the envelope of dengue virus. The assay showed moderate to strong correlations between epitope-blocking activities and virus-neutralizing antibody titers for each of the four dengue serotypes using blood samples from infected or immunized macaques.
MICROBIOLOGY SPECTRUM
(2023)
Article
Multidisciplinary Sciences
Hualong Xiong, Hui Sun, Siling Wang, Lunzhi Yuan, Liqin Liu, Yuhe Zhu, Jinlei Zhang, Yang Huang, Ruoyao Qi, Yao Jiang, Jian Ma, Ming Zhou, Yue Ma, Rao Fu, Siping Yan, Mingxi Yue, Yangtao Wu, Min Wei, Yizhen Wang, Tingting Li, Yingbin Wang, Zizheng Zheng, Hai Yu, Tong Cheng, Shaowei Li, Quan Yuan, Jun Zhang, Yi Guan, Qingbing Zheng, Tianying Zhang, Ningshao Xia
Summary: Antibody therapeutics for COVID-19 have been successful, but the emergence of the Omicron variant poses a challenge. Researchers have generated a panel of cross-neutralizing antibodies that can neutralize various variants of concern, with antibody X17 exhibiting strong neutralization against the Omicron variant. The antibodies bind to specific regions on the spike proteins of the viruses, enhancing resistance to viral evasion and providing effective protection against certain variants in animal models. These findings are important for the development of antibody therapeutics and broad-spectrum vaccines.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Cell Biology
Yannic C. Bartsch, Xin Tong, Jaewon Kang, Maria Jose Avendano, Eileen F. Serrano, Tamara Garcia-Salum, Catalina Pardo-Roa, Arnoldo Riquelme, Yongfei Cai, Isabella Renzi, Guillaume Stewart-Jones, Bing Chen, Rafael A. Medina, Galit Alter
Summary: Despite evading neutralizing antibodies, the Omicron variant does not increase death rates in highly vaccinated populations, suggesting the presence of immune mechanisms beyond antibody-mediated virus neutralization. Vaccine-induced Spike protein-specific antibodies continue to drive Fc effector functions, indicating the potential of extraneutralizing antibodies in disease control.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Virology
Lin Cheng, Shuo Song, Bing Zhou, Xiangyang Ge, Jiazhen Yu, Mingxia Zhang, Bin Ju, Zheng Zhang
Summary: The emergence and rapid spread of the B.1.1.7 SARS-CoV-2 variant has raised global concern. The N501Y substitution in this variant raised concerns about its recognition by neutralizing antibodies. Most detected antibodies were unaffected by this substitution, although CB6's neutralizing and binding activities decreased, while BD-23's increased. These findings could be valuable for therapeutic antibody development.
Article
Immunology
Rebecca L. Brocato, Steven A. Kwilas, Robert K. Kim, Xiankun Zeng, Lucia M. Principe, Jeffrey M. Smith, Jay W. Hooper
Summary: Global efforts to combat the COVID-19 pandemic have led to the development of numerous candidate vaccines in different stages of research and development. A DNA vaccine targeting the spike protein of SARS-CoV-2 demonstrated the ability to generate neutralizing antibodies and provide protection in hamster models, showing potential for further preclinical studies.
Article
Biotechnology & Applied Microbiology
Takamasa Hirai, Anna Sato, Naoya Koizumi, Yoh Kurioka, Yui Suzuki, Junpei Kano, Makie Yamakawa, Tetsuya Nomura, Makiko Fujii, Fuminori Sakurai, Hiroyuki Mizuguchi, Yoshiteru Watanabe, Naoki Utoguchi
Summary: This study evaluated the infectivity of progeny Ad serotype 5 (Ad5) in the presence of neutralizing antibodies (nAbs) and found that Ad5 could continue to infect cells even with nAbs present. A sorting system with magnetic beads was established to measure the infection levels of progeny Ad5, showing little difference in counts one day after infection in the presence or absence of nAbs. Moreover, progeny Ad5 in the presence of nAbs demonstrated more effective infection of coxsackievirus and adenovirus receptor (CAR)-positive cells compared to CAR-negative cells, suggesting a unique mechanism of infectivity.
JOURNAL OF GENERAL VIROLOGY
(2021)
Article
Microbiology
Anna Schachner, Carlotta De Luca, Sarah Heidl, Michael Hess
Summary: This study focuses on the development of chimeric fibers to induce cross-neutralizing antibodies and protective immune responses against inclusion body hepatitis caused by fowl adenovirus in chickens, providing a broad spectrum of protection. The results of this study contribute to the advancement of broadly protective subunit vaccination strategies.
MICROBIOLOGY SPECTRUM
(2022)
Article
Multidisciplinary Sciences
Pavlo Gilchuk, Isaac Thomsen, Sandra Yoder, Eric Brady, James D. Chappell, Laura J. Stevens, Mark R. Denison, Rachel E. Sutton, Rita E. Chen, Laura A. VanBlargan, Naveenchandra Suryadevara, Seth J. Zost, Jonathan Schmitz, Jill M. Pulley, Michael S. Diamond, Jillian P. Rhoads, Gordon R. Bernard, Wesley H. Self, Todd W. Rice, Allison P. Wheeler, James E. Crowe, Robert H. Carnahan
Summary: The COVID-19 pandemic has highlighted the urgent need for rapid evaluation of neutralizing antibody responses and the development of antibody-based treatments. The currently approved serological tests do not measure antibody-mediated viral neutralization, and there is a need for standardized quantitative neutralization assays. This study presents a high-throughput two-step profiling approach for identifying neutralizing convalescent plasma. Additionally, the researchers introduce a neutralizing antibody standard reagent to calibrate antibody neutralizing activity in convalescent plasma.
Article
Multidisciplinary Sciences
Prabhu S. Arunachalam, Alexandra C. Walls, Nadia Golden, Caroline Atyeo, Stephanie Fischinger, Chunfeng Li, Pyone Aye, Mary Jane Navarro, Lilin Lai, Venkata Viswanadh Edara, Katharina Roltgen, Kenneth Rogers, Lisa Shirreff, Douglas E. Ferrell, Samuel Wrenn, Deleah Pettie, John C. Kraft, Marcos C. Miranda, Elizabeth Kepl, Claire Sydeman, Natalie Brunette, Michael Murphy, Brooke Fiala, Lauren Carter, Alexander G. White, Meera Trisal, Ching-Lin Hsieh, Kasi Russell-Lodrigue, Christopher Monjure, Jason Dufour, Skye Spencer, Lara Doyle-Meyers, Rudolph P. Bohm, Nicholas J. Maness, Chad Roy, Jessica A. Plante, Kenneth S. Plante, Alex Zhu, Matthew J. Gorman, Sally Shin, Xiaoying Shen, Jane Fontenot, Shakti Gupta, Derek T. O'Hagan, Robbert Van Der Most, Rino Rappuoli, Robert L. Coffman, David Novack, Jason S. McLellan, Shankar Subramaniam, David Montefiori, Scott D. Boyd, JoAnne L. Flynn, Galit Alter, Francois Villinger, Harry Kleanthous, Jay Rappaport, Mehul S. Suthar, Neil P. King, David Veesler, Bali Pulendran
Summary: This study demonstrated the effectiveness of an adjuvanted RBD-NP vaccine in inducing robust and durable neutralizing antibody responses, providing protection against SARS-CoV-2 infection, and cross-neutralizing various variants. Adjuvants such as AS03 and AS37 significantly enhanced the immunogenicity of the vaccine and have the potential to be candidates for COVID-19 vaccines.
Article
Virology
Haisu Yi, Qian Wang, Hengchun Li, Yingkun Zhang, Zhilong Chen, Tianxin Ji, Wenming Liu, Xuehua Zheng, Qinghua Ma, Xinxin Sun, Yudi Zhang, Xuegao Yu, Mengzhang He, Ling Chen, Ying Feng
Summary: This study revealed the seroprevalence of neutralizing antibodies against HAdV26 and HAdV35 in the general population of Guangdong and Shandong provinces in China. The results highlighted differences in seropositive rates between the two adenoviruses and their associations with age and region.
Review
Immunology
Chia-Jung Li, Shih-Chung Chang
Summary: Since the onset of COVID-19, numerous NAbs against SARS-CoV-2 have been developed, but the emergence of immune escape variants threatens their effectiveness. However, NAbs targeting the S2 subunit of the S protein may offer broader neutralizing potency. This review discusses the binding specificity and functional features of S2-specific NAbs, providing insights for antibody cocktail therapy and next-generation vaccines.
EMERGING MICROBES & INFECTIONS
(2023)
Article
Immunology
Qian Wu, Ling Zhong, Dongmei Wei, Wanlin Zhang, Junping Hong, Yinfeng Kang, Kaiyun Chen, Yang Huang, Qingbing Zheng, Miao Xu, Mu-Sheng Zeng, Yi-Xin Zeng, Ningshao Xia, Qinjian Zhao, Claude Krummenacher, Yixin Chen, Xiao Zhang
Summary: Epstein-Barr virus (EBV) is a human oncogenic virus that infects more than 95% of the global population. Antibodies 1A7 and 6G7 have been identified as potent neutralizers against B cell infection. Specifically, antibody 6G7 provides protection against lethal EBV challenge and EBV-induced lymphoma in humanized mice.
EMERGING MICROBES & INFECTIONS
(2023)
